Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Mundipharma announces EU regulatory submission for Nyxoid®

Posted on: 02 Nov 16
  • Mundipharma makes first EU regulatory submission for Nyxoid® (intranasal naloxone spray)

for the reversal of opioid overdose

  • Novel formulation designed to support take-home naloxone programmes and provide ‘first

responders’ in overdose situations with an easy to use, needle-free option

  • Drug-induced deaths represent a significant public health problem in the EU, the majority of

which are associated with heroin[1]


Cambridge, UK – 2 November, 2016 Mundipharma today announced the submission of a

Marketing Authorisation Application (MAA) for Nyxoid® (intranasal naloxone 1.8 mg in 0.1 ml)[2] to

the European Medicines Agency (EMA), seeking approval for the emergency reversal of opioid



Naloxone has been used in routine practice to reverse the effects of opioid overdose for more than

40 years,[3] and is included in the World Health Organisation (WHO) List of Essential Medicines.[4] An

intranasal formulation has been developed by Mundipharma in order to provide potential ‘first

responders’ in overdose situations with an easy to use, needle-free option that is suitable for use in

a take-home naloxone setting.


Rachel Gooch, Head of Addiction Therapy at Mundipharma International Limited, said: “We know

that in emergency circumstances, rapid administration of a reversal agent is critical to preserving

life. Take-home programmes are intended to increase the availability of naloxone in places where

overdoses are most likely to occur, and provide prompt treatment that can save lives. We are

pleased to be playing a role in providing essential medicines like naloxone, as well as taking a

significant step towards building a portfolio of treatment options in addiction medicine.”


Mundipharma’s submission is based on data from a recently performed 5 part, single site, open

label, randomised, single dose, crossover study involving 38 healthy volunteers. This study showed

that Nyxoid is bioequivalent to injectable naloxone as a first line treatment for opioid overdose, with

an intranasal 1.8 mg dose* anticipated to deliver therapeutic concentrations comparable with a 0.4

mg intramuscular naloxone, currently regarded as the standard of care in the event of opioid

overdose.[5] The product is well tolerated with a similar safety profile to that of injectable naloxone.5



* Nyxoid contains 1.8 mg naloxone, which is equivalent to 2 mg naloxone hydrochloride.

Editor's Details

Mike Wood

Last updated on: 02/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.